Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Inozyme Pharma Inc (INZY)

Inozyme Pharma Inc (INZY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,690
  • Shares Outstanding, K 40,394
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,620 K
  • 60-Month Beta 0.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.55
Trade INZY with:

Options Overview Details

View History
  • Implied Volatility 276.87% ( +115.28%)
  • Historical Volatility 134.64%
  • IV Percentile 68%
  • IV Rank 36.60%
  • IV High 749.64% on 12/06/22
  • IV Low 3.92% on 10/07/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 109
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 308
  • Open Int (30-Day) 220

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.46
  • Number of Estimates 6
  • High Estimate -0.41
  • Low Estimate -0.54
  • Prior Year -0.79
  • Growth Rate Est. (year over year) +41.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9900 +111.91%
on 12/30/22
2.1700 -3.23%
on 01/26/23
+0.9000 (+75.00%)
since 12/23/22
3-Month
0.9900 +111.91%
on 12/30/22
2.4000 -12.50%
on 10/27/22
-0.0900 (-4.11%)
since 10/26/22
52-Week
0.9900 +111.91%
on 12/30/22
7.9800 -73.68%
on 02/11/22
-5.0400 (-70.59%)
since 01/26/22

Most Recent Stories

More News
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief...

ACHN : 0.1200 (unch)
ARVN : 31.24 (-3.46%)
NXTC : 1.6100 (-8.00%)
BHVN : 18.54 (-3.13%)
INZY : 2.1000 (+20.00%)
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.

AZN : 65.99 (-0.96%)
SRNE : 0.9600 (-4.95%)
PLRX : 36.26 (+4.65%)
INZY : 2.1000 (+20.00%)
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.

BLUE : 6.23 (-1.58%)
RYTM : 30.47 (-1.71%)
PLRX : 36.26 (+4.65%)
INZY : 2.1000 (+20.00%)
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment

Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.

AGLE : 0.4930 (+2.71%)
RYTM : 30.47 (-1.71%)
PLRX : 36.26 (+4.65%)
INZY : 2.1000 (+20.00%)
bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia

bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.

BLUE : 6.23 (-1.58%)
STRO : 7.49 (-3.35%)
IMVT : 17.60 (-4.71%)
INZY : 2.1000 (+20.00%)
Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study

Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.

STRO : 7.49 (-3.35%)
ARTL : 3.21 (+3.22%)
IMVT : 17.60 (-4.71%)
INZY : 2.1000 (+20.00%)
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

BMRN : 116.98 (+0.82%)
EPZM : 1.4700 (-1.34%)
APTX : 0.4055 (-1.41%)
INZY : 2.1000 (+20.00%)
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...

INZY : 2.1000 (+20.00%)
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) – - INZ-701 was...

INZY : 2.1000 (+20.00%)
How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%

The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

INZY : 2.1000 (+20.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston,...

See More

Key Turning Points

3rd Resistance Point 2.6100
2nd Resistance Point 2.3900
1st Resistance Point 2.2500
Last Price 2.1000
1st Support Level 1.8800
2nd Support Level 1.6600
3rd Support Level 1.5100

See More

52-Week High 7.9800
Fibonacci 61.8% 5.3100
Fibonacci 50% 4.4900
Fibonacci 38.2% 3.6600
Last Price 2.1000
52-Week Low 0.9900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar